122 related articles for article (PubMed ID: 32965131)
21. Healthcare costs associated with breast cancer in Germany: a claims data analysis.
Kreis K; Plöthner M; Schmidt T; Seufert R; Schreeb K; Jahndel V; Maas S; Kuhlmann A; Zeidler J; Schramm A
Eur J Health Econ; 2020 Apr; 21(3):451-464. PubMed ID: 31897812
[TBL] [Abstract][Full Text] [Related]
22. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
[TBL] [Abstract][Full Text] [Related]
23. Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer.
Schwartz NR; DeBusk K; Forero-Torres A; Feliciano J; Anupindi VR; Yeaw J; McBride A
Future Oncol; 2021 Sep; 17(26):3457-3463. PubMed ID: 34044579
[No Abstract] [Full Text] [Related]
24. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Benjamin L; Buthion V; Iskedjian M; Farah B; Rioufol C; Vidal-Trécan G
J Med Econ; 2013; 16(1):96-107. PubMed ID: 22970840
[TBL] [Abstract][Full Text] [Related]
25. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
27. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
28. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
29. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
31. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands.
Schneider PP; Ramaekers BL; Pouwels X; Geurts S; Ibragimova K; de Boer M; Vriens B; van de Wouw Y; den Boer M; Pepels M; Tjan-Heijnen V; Joore M
Value Health; 2021 May; 24(5):668-675. PubMed ID: 33933235
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
33. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data.
Shim YB; Byun JY; Lee JY; Lee EK; Park MH
PLoS One; 2022; 17(9):e0274876. PubMed ID: 36126084
[TBL] [Abstract][Full Text] [Related]
35. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
36. Long-term medical costs of postmenopausal breast cancer therapy.
Cocquyt V; Moeremans K; Annemans L; Clarys P; Van Belle S
Ann Oncol; 2003 Jul; 14(7):1057-63. PubMed ID: 12853347
[TBL] [Abstract][Full Text] [Related]
37. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
39. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
40. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
